| Name | Malotilate |
| Description | Malotilate (Kantec) is a medicine used for the therapy of liver cirrhosis. |
| In vitro | Malotilate caused a significant decrease in the invasion of C-SST-2 cells in RLE monolayers.Malotilate inhibited the increased permeability of RLE monolayers by serum starvation. By enhancing the intercellular contact of endothelial cells, Malotilate prevented the invasion of tumor cells into the vascular endothelium and inhibited tumor metastasis. In multilayer cultures, Malotilate (0.1-100 μM) concentration-dependently increased collagenase activity but did not affect monolayer cells. In damaged multilayer cultures, Malotilate increased MMP-1 and MMP-3 secretion, also without affecting monolayer cells. |
| In vivo | Malotilate caused a significant decrease in the invasion of C-SST-2 cells in RLE monolayers.Malotilate inhibited the increased permeability of RLE monolayers by serum starvation. By enhancing the intercellular contact of endothelial cells, Malotilate prevented the invasion of tumor cells into the vascular endothelium and inhibited tumor metastasis. In multilayer cultures, Malotilate (0.1-100 μM) concentration-dependently increased collagenase activity but did not affect monolayer cells. In damaged multilayer cultures, Malotilate increased MMP-1 and MMP-3 secretion, also without affecting monolayer cells. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.94 mM), Sonication is recommended.
Ethanol : 58 mg/mL (201.12 mM), Sonication is recommended.
DMSO : 55 mg/mL (190.72 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | synthesis | oral | NKK-105 | NKK105 | migration | Malotilate | LOX | Lipoxygenase | injury | Inhibitor | inhibit | hepatotropic | collagen | cell | anti-fibrotic | 5-Lipoxygenase |
| Inhibitors Related | 2,5-Di-tert-butylhydroquinone | Caffeic Acid | 5-LOX inhibitor | 3-Aminobutanoic acid | Phenidone | 4-Aminosalicylic acid | Cuminaldehyde | NNK | Shogaol | PF-4191834 | 5-Aminosalicylic Acid | Tebufelone |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | NO PAINS Compound Library | Anti-Fibrosis Compound Library | Metabolism Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | NMPA-Approved Drug Library |
United States
